{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:54:40Z","timestamp":1793073280536,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007786","name":"National Center for Child Health and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ymgme.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T13:55:50Z","timestamp":1532354150000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS"],"prefix":"10.1016","volume":"125","author":[{"given":"Noboru","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiho","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.07.013_bb0005","first-page":"104","article-title":"A rare disease in two brothers","volume":"10","author":"Hunter","year":"1917","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0015","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2004.01.052","article-title":"The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations","volume":"144","author":"Muenzer","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0020","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/adc.57.11.828","article-title":"Mild form of Hunter's syndrome: clinical delineation based on 31 cases","volume":"57","author":"Young","year":"1982","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0025","first-page":"253","article-title":"Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome)","volume":"15","author":"Papadia","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0030","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0045","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4\u20137.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","volume":"16","author":"Giugliani","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","article-title":"Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed","volume":"31","author":"Al Sawaf","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0060","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain barrier-penetrating anti-human transferrin receptor antibody fusion protein for neurologic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1471-4159.1970.tb00508.x","article-title":"Acid mucopolysaccharides in the cerebrospinal fluid of patients with Hunter-Hurler's syndrome","volume":"17","author":"Constantopoulos","year":"1970","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ymgmr.2015.11.001","article-title":"Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment","volume":"5","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0075","doi-asserted-by":"crossref","DOI":"10.1177\/2326409815595821","article-title":"A cerebrospinal fluid collection study in pediatric and adult patients with Hunter syndrome","volume":"3","author":"Hendriksz","year":"2015","journal-title":"J. Inborn. Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0080","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1373\/clinchem.2010.161141","article-title":"Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry","volume":"57","author":"Zhang","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0085","doi-asserted-by":"crossref","first-page":"17.12.1","DOI":"10.1002\/0471142905.hg1712s76","article-title":"Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry","volume":"76","author":"Zhang","year":"2013","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2014.09.009","article-title":"A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparin sulfate, dermatan sulfate and chondroitin sulfate in urine: An improved clinical screening test for the mucopolysaccharidoses","volume":"114","author":"Zhang","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/abio.1997.2494","article-title":"Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis","volume":"256","author":"Bj\u00f6rnsson","year":"1998","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2010.09.003","article-title":"Efficient analysis of urinary glycosaminoglycans by LC-MS\/MS in mucopolysaccharidoses type I, II and VI","volume":"102","author":"Auray-Blais","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgme.2016.09.005","article-title":"Glycosaminoglycans detection methods: Applications of mass spectrometry","volume":"120","author":"Kubaski","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0110","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","article-title":"Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression","volume":"146A","author":"Munoz-Rojas","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2018.07.013_bb0115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","article-title":"Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?","volume":"75","author":"W\u0119grzyn","year":"2010","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ymgme.2018.07.013_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcdb.2004.03.002","article-title":"Secondary accumulation of gangliosides in lysosomal storage disorders","volume":"15","author":"Walkley","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1006\/exnr.2000.7602","article-title":"Selective cell-cycle arrest and induction of apoptosis in proliferating neural cells by ganglioside GM3","volume":"168","author":"Nakatsuji","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2018.07.013_bb0130","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile GM2 gangliosidosis","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2018.07.013_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T20:19:19Z","timestamp":1538684359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218301124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":27,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1096719218301124"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}